The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Purpose Pre-clinical and early clinical data suggests the microbiome plays an important role in oncogenesis and influences response to immune checkpoint blockade (ICB). The objective of this systematic review and meta-analysis was to determine whether antibiotics affect overall survival (OS) and progression free survival (PFS) in patients with solid malignancies treated with ICB.Patients and methods A systematic search of EMBASE, MEDLINE and conference proceedings was conducted for observational studies examining the effect of antibiotics on ICB. A random effects study-level meta-analysis was performed with pooling of the hazards ratio (HR) for OS and PFS. Meta-regression was used to determine the impact of the timing of antibiotic exposure on OS.Results 766 studies were identified, and 18 studies met the inclusion criteria. Of the 2889 patients included, 826 (28.6%) were exposed to antibiotics. The most common malignancies were lung (59%), renal cell carcinoma (RCC) or urothelial carcinoma (16.3%) and melanoma (18.7%). OS was prolonged in those without antibiotic exposure (pooled HR 1.92, 95% CI 1.37-2.68, p < 0.001). The effect of antibiotics on OS was greater in studies defining antibiotic exposure as 42 days prior to initiation of ICB (HR 3.43, 95% CI 2.29-5.14, p < 0.0001). PFS was also longer in patients who did not receive antibiotics (pooled HR 1.65, 95% CI 1.3-2.1, p < 0.0001).Conclusion In patients receiving ICB, OS and PFS are longer in patients who are not exposed to antibiotics. Antibiotic use in the 42 days before starting ICB appears to be most detrimental to outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, retrospective studies have implicated that antibiotics were associated with decreased survival and attenuated response to ICI in patients with advanced solid tumors [39–44], supporting a causal link between antibiotic-induced dysbiosis and poor therapeutic efficacy of ICI.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357
Research works printed but not linked: 3
- Schett ARS, Mauti LA, Schmid S, Appenzeller C, Curioni-Fontecedro A, Frueh M, Joerger M (2019) Progsnotic impact of the use of antibiotics in patients with advanced non-small cell lung cancer receiving PD-(L)1 targeting monoclonal antibodies. Ann Oncol 30(Supplemental 2):157
- Derosa L, Routy B, Enot D, Fidelle M, Gubet AG, Goldwasser F, Zitvogel L, Loriot Y, Albiges L, Escudier B (2018) Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Kidney Cancer 2(Supplement 1):S24–S25
- Wilson BE, Routy B, Nagrial A, Chin V (2019) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Asia-Pacific J Clin Oncol 15(supplemental 9):359
Cited by
Butyrate-producing human gut symbiont, Clostridium butyricum , and its role in health and disease
Stoeva, M. K., Garcia-So, J., Justice, N., Myers, J., Tyagi, S., Nemchek, M., McMurdie, P. J., Kolterman, O., & Eid, J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1907272 · Cited by 518
“Exposure to antibiotics prior to receiving ICB therapy is especially detrimental to the outcome.(124) Recently, first-in-human clinical trials showed that fecal microbiota transplantation (FMT) improved the efficacies of anti-PD-1 immunotherapy in patients with anti-PD-1-refractory metastatic melanoma, while also repr…”
BackgroundGut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316
Self-citationCancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0808 · Cited by 250
Self-citationHelicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Oster, P., Vaillant, L., Riva, E., McMillan, B., Begka, C., Truntzer, C., Richard, C., Leblond, M. M., Messaoudene, M., Machremi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323392 · Cited by 176
“Together with the known detrimental effect of antibiotic administration on the efficacy of immunotherapies in cancer patients, 6 29 this result suggests that antibiotic administration to cure H. pylori infection is most likely a poor option to increase the efficacy of cancer immuno-therapies in…”
Self-citationMicrobiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?
Derosa, L., Routy, B., Desilets, A., Daillère, R., Terrisse, S., Kroemer, G., & Zitvogel, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0236 · Cited by 170
Self-citationGut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
“…fi cantly longer OS than those who received antibiotics within 60 days prior to treatment, which is consistent with previous fi ndings, as the microbiota returned to near-baseline levels within 42 days after administration of an antibiotic cocktail regimen (ABX) for 4 days to healthy adults 208,232 .”
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 166
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
Pu, T., Sun, J., Ren, G., & Li, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02241-8 · Cited by 171
Fatty acid metabolism of immune cells: a new target of tumour immunotherapy
Zhang, S., Lv, K., Liu, Z., Zhao, R., & Li, F. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01807-9 · Cited by 152
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
“Multiple retrospective studies have reported that antibiotic use is correlated with reduced survival and a blunted response to ICB in patients with advanced solid tumors, implying that antibiotics may impair ICB ef fi cacy by inducing gut microbial dysbiosis [105 – 109].”
Eng, L., Sutradhar, R., Niu, Y., Liu, N., Liu, Y., Kaliwal, Y., Powis, M. L., Liu, G., Peppercorn, J. M., Bedard, P. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00074 · Cited by 105
“Univariate and Multivariate Association Analysis of Covariates on Overall Survival After Starting ICI Therapy Variable Comparison Univariable Analysis Multivariable Analysis HR (95% CI) P aHR (95% CI) P Sex Female v male 1.02 (0.93 to 1.13) .68 0.98 (0.88 to 1.08) .64 Age Per 1-year increase 1.00 (1.00 to 1.01) .29 1.…”
BackgroundInfluentialKostine, M., Mauric, E., Tison, A., Barnetche, T., Barre, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.036 · Cited by 101
Lee, K. A., Shaw, H. M., Bataille, V. A., Nathan, P., & Spector, T. D. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.026 · Cited by 94
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0374-6 · Cited by 81
Tsikala-Vafea, M., Belani, N., Vieira, K., Khan, H., & Farmakiotis, D. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.063 · Cited by 75
The gut microbiome and efficacy of cancer immunotherapy
Roviello, G., Iannone, L. F., Bersanelli, M., Mini, E., & Catalano, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107973 · Cited by 84
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Yan, S., Wang, W., Feng, Z., Xue, J., Liang, W., Wu, X., Tan, Z., Zhang, X., Zhang, S., Li, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403533 · Cited by 91
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
Mohindroo, C., Hasanov, M., Rogers, J. E., Dong, W., Prakash, L. R., Baydogan, S., Mizrahi, J. D., Overman, M. J., Varadhachary, G. R., Wolff, R. A., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3870 · Cited by 79
Crespin, A., Bescop, C. L., de Gunzburg, J., Vitry, F., Zalcman, G., Cervesi, J., & Bandinelli, P.-A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1075593 · Cited by 88
Konen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 82
Tumor-Associated Microbiome: Where Do We Stand?
Oliva, M., Mulet-Margalef, N., Ochoa-de-Olza, M., Napoli, S., Mas-Lloret, J., Laquente, B., Alemany, L., Duell, E. J., Nuciforo, P. G., & Moreno, V. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031446 · Cited by 65
Spakowicz, D., Hoyd, R., Muniak, M., Husain, M., Bassett, J. S., Wang, L., Tinoco, G., Patel, S. H., Burkart, J., Miah, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06882-6 · Cited by 62
Tsiogka, A., Bauer, J., & Patsatsi, A. (2021) · Acta Dermato Venereologica · doi:10.2340/00015555-3740 · Cited by 65
Yang, M., Wang, Y., Yuan, M., Tao, M., Kong, C., Li, H., Tong, J., Zhu, H., & Yan, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106876 · Cited by 63
Huang, C.-L., Li, M., Liu, B., Zhu, H., Dai, Q., Fan, X., Mehta, K. D., Huang, C. H., Neupane, P. C., Wang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642110 · Cited by 68
Hopkins, A. M., Badaoui, S., Kichenadasse, G., Karapetis, C. S., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.02.003 · Cited by 55
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 71
“40 For example, observational studies have exhibited an inverse correlation between antibiotic treatment and the positive outcomes of ICI administration, 41–44 suggesting that gut microbiome integrity and gut-trained immunity regulate the effectiveness of ICI therapy.”
BackgroundThe gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice
Asseri, A. H., Bakhsh, T., Abuzahrah, S. S., Ali, S., & Rather, I. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1208044 · Cited by 59
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
Wang, G., He, X., & Wang, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188846 · Cited by 52
Zhang, L., Chen, C., Chai, D., Li, C., Guan, Y., Liu, L., Kuang, T., Deng, W., & Wang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956533 · Cited by 54
Wheatley, R. C., Kilgour, E., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01583-8 · Cited by 49
Nyein, A., Bari, S., Hogue, S., Zhao, Y., Maller, B., Sha, S. T., Gómez, M. F. L., Rollison, D. E. M., & Robinson, L. A. (2022) · BMC Cancer · doi:10.1186/s12885-022-09210-2 · Cited by 54
“Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of NSCLC, markedly improving response rates and survival [10].”
ResultInfluentialZhang, F., Ferrero, M., Dong, N., D’Auria, G., Reyes-Prieto, M., Herreros-Pomares, A., Calabuig-Fariñas, S., Duréndez, E., Aparisi, F., Blasco, A., et al. (2021) · Cancers · doi:10.3390/cancers13112514 · Cited by 43
“Interestingly, some reports have demonstrated that the use of ATB is a negative factor in the effectiveness and clinical outcomes to ICB [29,33,34].”
BackgroundKubeček, O., Paterová, P., & Novosadová, M. (2021) · Life · doi:10.3390/life11121387 · Cited by 60
Chambers, L., Kuznicki, M. L., Yao, M., Chichura, A. M., Gruner, M., Reizes, O., Debernardo, R. L., Rose, P. G., Michener, C. M., & Vargas, R. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.010 · Cited by 43
Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
Parent, P., Marcq, G., Adeleke, S. M., Turpin, A., Boussios, S., Rassy, E., & Penel, N. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231192402 · Cited by 43
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Belluomini, L., Caldart, A., Avancini, A., Dodi, A., Trestini, I., Kadrija, D., Sposito, M., Tregnago, D., Casali, M., Riva, S. T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010042 · Cited by 43
Wu, Q., Liu, J., Wu, S., & Xie, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107303 · Cited by 43
Kulkarni, A. A., Ebadi, M., Zhang, S., Meybodi, M. A., Ali, A. M., DeFor, T. E., Shanley, R., Weisdorf, D. J., Ryan, C. J., Vasu, S., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000803 · Cited by 37
Microbiome influencers of checkpoint blockade–associated toxicity
Wang, Y., Jenq, R. R., Wargo, J. A., & Watowich, S. S. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220948 · Cited by 37
“Consistently, broad-spectrum antibiotic treatment renders poor therapeutic response (Routy et al., 2018b; Wilson et al., 2020).”
BackgroundInfluence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
“A comprehensive meta-analysis has noted that patients without antibiotic exposure within 42 days before commencing ICI therapy had 3.43 times longer OS than those who received antibiotics within 60 days preceding ICI initiation [308].”
BackgroundInfluentialLu, P., Tsai, T., Chang, J. W., Deng, S., & Cheng, C. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13298 · Cited by 31
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
Araujo, D. V., Watson, G. A., Oliva, M., Heirali, A., Coburn, B., Spreafico, A., & Siu, L. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102125 · Cited by 29
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
Yavuz, B. G., Datar, S. S., Chamseddine, S., Mohamed, Y. I., LaPelusa, M. B., Lee, S. S., Hu, Z. I., Koay, E. J., Cao, H. S. T., Jalal, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15194875 · Cited by 34
“Several meta-analyses have reported worse outcomes in patients with lung, melanoma, bladder, and kidney cancers treated with ICIs who were concomitantly administered antibiotics, possibly altering the balance between favorable and unfavorable bacterial species [47,48].”
BackgroundScoping review protocol on the impact of antimicrobial resistance on cancer management and outcomes
Bratti, V. F., Wilson, B. E., Fazelzad, R., Pabani, A., Zürn, S. J., Johnson, S., Sung, L., & Rodin, D. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068122 · Cited by 28
Self-citationBredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 29
Cancer and immunotherapy: a role for microbiota composition
Pham, F., Moinard‐Butot, F., Coutzac, C., & Chaput, N. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.051 · Cited by 29
Li, H., Zhang, L., Yang, F., Zhao, R., Li, X., & Li, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1218386 · Cited by 36
Wu, M., Tian, C., Zou, Z., Min, J., & Liu, H. (2024) · Cancers · doi:10.3390/cancers16203547 · Cited by 29
“Patients who refrained from using antibiotics within 42 days prior to starting ICB therapy experienced a 3.43-fold increase in overall survival compared to those who had used antibiotics within 60 days before ICB therapy [150].”
BackgroundInfluentialAntibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
Meriggi, F. A., & Zaniboni, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02786-3 · Cited by 29
Poizeau, F., Kerbrat, S., Balusson, F., Tattevin, P., Revest, M., Cattoir, V., Paz, D. L., Lesimple, T., Pracht, M., Dinulescu, M., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac019 · Cited by 28
Cvetkovic, L., Régis, C., Richard, C., Derosa, L., Leblond, A., Malo, J., Messaoudene, M., Desîlets, A., Belkaïd, W., Elkrief, A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05081-6 · Cited by 24
Self-citationFirst clinical proof-of-concept that FMT can overcome resistance to ICIs
Elkrief, A., & Routy, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00502-3 · Cited by 23
Self-citationvon Itzstein, M. S., Gonugunta, A. S., Sheffield, T. Y., Homsi, J., Dowell, J. E., Koh, A. Y., Raj, P., Fattah, F. J., Wang, Y., Basava, V. S., et al. (2022) · Cancers · doi:10.3390/cancers14051327 · Cited by 24
Antibiotics, cancer risk and oncologic treatment efficacy: a practical review of the literature
Lopes, M. S. M., Machado, L. M., Silva, P. A. I. A., Uchiyama, A. A. T., Yen, C. T., Ricardo, E. D., Mutão, T. S., Pimento, J. R., Shimba, D. S., Hanriot, R. D. M., et al. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1106 · Cited by 28
“0001), indicating that the timing of antibiotic exposure in relation to ICI is also relevant [69].”
BackgroundChen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 24
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
“In NSCLC and RCC, observational cohorts have prospectively linked baseline microbial diversity and enrichment of taxa such as Akkermansia muciniphila with superior outcome [10,11].”
Gut Microbiota and Immunotherapy
Xu, X., & Ying, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.945887 · Cited by 25
Vion, R., Dugage, M. R., Flippot, R., Ouali, K., Rouanne, M., Clatot, F., Sellars, M., Champiat, S., Chaput, N., Massard, C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115572 · Cited by 23
A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine
Mokhtari, R. B., Sambi, M., Shekari, F., Satari, K., Ghafoury, R., Ashayeri, N., Eversole, P., Baluch, N., Harless, W. W., Muscarella, L. A., et al. (2025) · Biomolecules · doi:10.3390/biom15091304 · Cited by 25
The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
Deluce, J. E., Vareki, S. M., & Fernandes, R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221122714 · Cited by 22
Gut microbiota: a potential target for improved cancer therapy
Zhao, M., Jiang, G., Zhou, H., Li, J., Xiang, W., Li, S., Wang, H., & Zhou, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04546-5 · Cited by 20
“A meta-analysis study of multiple cancers treated with ICI showed that patients without ATB who were treated with ICI had significantly longer OS (Wilson et al. 2019).”
MethodMicrobiota: A key factor affecting and regulating the efficacy of immunotherapy
Jiang, Y., Jia, D., Sun, Y., Ding, N., & Wang, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1508 · Cited by 22
“94 Several studies have shown that the use of antibiotics attenuates the efficacy of ICIs in a variety of tumour types (melanoma, NSCLC, uroep-ithelial cancer, gastroesophageal cancer, pancreatic cell carcinoma, etc.).”
BackgroundThe Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer
Guo, Q., Qin, H., Liu, X., Zhang, X., Chen, Z., Qin, T., Chang, L., & Zhang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915047 · Cited by 25
Immuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 28
The Microbiome and Infectious Diseases
Haraoui, L., & Blaser, M. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad577 · Cited by 19
A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids
Yu, Y., Gao, L., Wang, Y., Xu, B., Maswikiti, E. P., Li, H., Peng, Z., Tao, P., Xiang, L., Gu, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751086 · Cited by 19
Morrell, S. L., Kohonen‐Corish, M. R. J., Ward, R. L., Sorrell, T. C., Roder, D. M., & Currow, D. C. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.04.003 · Cited by 18
Gut microbiota and immunotherapy of renal cell carcinoma
Bibbò, S., Porcari, S., Vecchio, L. E. D., Severino, A., Mullish, B. H., Ianiro, G., Gasbarrini, A., & Cammarota, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2268982 · Cited by 20
“71,72”
Abdelhamid, A., Tuminello, S., Ivic‐Pavlicic, T., Flores, R. M., & Taioli, E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-597 · Cited by 20
Chorti, E., Kowall, B., Hassel, J. C., Schilling, B., Sachse, M., Gutzmer, R., Loquai, C., Kähler, K. C., Hüsing, A., Gilde, C., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113536 · Cited by 19
Huang, L., Chen, X., Zhou, L. Q., Xu, Q., Xie, J., Zhan, P., Lv, T., & Song, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2076 · Cited by 19
Efficacy of timing‑dependent infusion of nivolumab in patients with advanced gastric cancer
Tanaka, T., Suzuki, H., Yamaguchi, S., Shimotsuura, Y., Nagasu, S., Murotani, K., Fujita, F., Kawaguchi, T., & Miwa, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14596 · Cited by 15
Daillère, R., Routy, B., Goubet, A., Cogdill, A. P., Ferrere, G., Silva, C. A.-C., Fluckiger, A., Ly, P., Haddad, Y., Pizzato, E., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1794423 · Cited by 17
Self-citationLuo, Z., Hao, S., Li, Y., Cheng, L., Zhou, X., Gunes, E. G., Liu, S., & Chen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1065004 · Cited by 17
AI finds microbial signatures in tumours and blood across cancer types
Ajami, N. J., & Wargo, J. A. (2020) · Nature · doi:10.1038/d41586-020-00637-w · Cited by 16
Sun, Y., Jiang, L., Wen, T., Guo, X., Shao, X., Qu, H., Chen, X., Song, Y., Wang, F., Qu, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670900 · Cited by 14
“The article captured the attention and interest of scientists and contributed to several further metaanalyses (Lurienne et al., 2020; Wilson et al., 2020; Yang et al., 2020), which indicated the ability of meta-analysis to reflect and explore key issues in the field.”
BackgroundPoletto, S., Paruzzo, L., Nepote, A., Caravelli, D., Sangiolo, D., & Carnevale‐Schianca, F. (2023) · Cancers · doi:10.3390/cancers16010101 · Cited by 15
Amadei, S. S., & Notario, V. (2020) · Antibiotics · doi:10.3390/antibiotics9090580 · Cited by 12
“Since then, most studies have reported negative effects of antibiotic exposure leading to diminished levels of efficacy of ICIs in immunotherapy protocols for the treatment of a variety of tumors, including lung tumors/NSCLC [137–144], advanced or metastatic renal cell carcinoma [137,141,142,144], urothelial carcinoma…”
BackgroundBairi, K. E., Jabi, R., Trapani, D., Boutallaka, H., Bencheikh, B. O. A., Bouziane, M., Amrani, M., Afqir, S., & Maleb, A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1758063 · Cited by 12
“These findings were supported by an up to date meta-analysis of 18 observational studies (2889 patients) [87].”
ResultInsights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
Jani, S., Church, C. D., & Nghiem, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172913 · Cited by 12
Immunotherapy response-associated Akkermansia: canary in a coal mine?
Cascone, T., Chelvanambi, M., & Wargo, J. A. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.03.007 · Cited by 10
A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
Piao, X., Byun, Y. J., Zheng, C.-M., Song, S. J., Kang, H. W., Kim, W. T., & Yun, S. J. (2023) · Cancers · doi:10.3390/cancers15030935 · Cited by 12
Kadhim, A. S., & Al-Karawi, A. S. (2023) · American Journal of Bioscience and Bioinformatics · doi:10.54536/ajbb.v2i1.1910 · Cited by 14
“…scrutiny was done to evaluate the efficiency of an enhanced high-throughput, semi-automated technique in detecting and assessing clarithromycin susceptibility of H. pylori in unpreserved fecal and stomach specimens, as compared to a previously described manual procedure (Wilson et al ., 2020).”
MethodMajumder, B., Nataraj, N. B., Maitreyi, L., & Datta, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1414376 · Cited by 11
Tamura, K., Okuma, Y., Nomura, S., Fukuda, A., Masuda, K., Matsumoto, Y., Shinno, Y., Yoshida, T., Goto, Y., Horinouchi, H., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05649-x · Cited by 9
Impact of Antimicrobial Resistance in Health and Economic Outcomes: A Review
Upaganlawar, A. B. (2024) · Advances in Pharmacology & Clinical Trials · doi:10.23880/apct-16000234 · Cited by 7
Spakowicz, D. J., Bibi, A., Muniak, M., Williams, N. F., Hoyd, R., & Presley, C. J. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.001 · Cited by 8
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
Giglio, A. D., Federico, A. D., Deiana, C., Ricciuti, B., Brambilla, M., & Metro, G. (2022) · Drugs in Context · doi:10.7573/dic.2022-2-4 · Cited by 8
Yin, L., Lv, B., Ge, J., Qi, Y., Xia, J., Ma, S., Wang, Y., Liu, Y., Zhou, D., Cao, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1566016 · Cited by 8
Nieves, L. M., Roach, A., Hunter, J., Smeh, S., Islas, A., Islas, A. K. F., Blattman, J. N., & DiPalma, M. P. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1577108 · Cited by 7
Microbiota-derived metabolites as modulators of cancer immunotherapy response
Toner-Bartelds, C., Mimpen, I. L., Parra-Martinez, M., Burgering, B. M. T., & Voest, E. E. (2026) · Nature Communications · doi:10.1038/s41467-026-72178-1 · Cited by 10
“A fi rsthint for a role of the microbiome in ICB response came from studies showing that antibiotic treatment prior to or during ICB treatment results in a worsened response 4,5 .”
Drobner, J. C., Lichtbroun, B. J., Singer, E. A., & Ghodoussipour, S. B. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231164196 · Cited by 8
“Treatment with antibiotics prior to ICI therapy was shown to be more harmful than antibiotic use after ICI therapy.(20) Derosa et al.”
MethodWu, Q., Zhang, S., Hua, X., Yu, H., & Zhong, Y. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1485 · Cited by 7
“Indeed, there were a few studies showing previous use of antibiotics might dampen the effect of immunotherapy (5-8).”
BackgroundChen, J., Chen, S., Luo, H., Long, S., Yang, X., He, W., Wu, W., & Wang, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110919 · Cited by 7
Deng, F., Du, X., Zhang, P., Xu, J., Li, Y., & Yang, Z. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15490 · Cited by 8
Bonnefin, C., Schneider, S., Gerard, É., Dutriaux, C., Ferté, T., Prey, S., Guicheney, M., Ducharme, O., Pédeboscq, S., Beylot-Barry, M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115223 · Cited by 6
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 8
“[112] Notably, Ochi et al [113] found that the use of ATB had a differential impact on the efficacy of ICI in advanced NSCLC patients based on PD-L1 expression levels.”
Metadata
- Authors
- Wilson, B. E., Routy, B., Nagrial, A., & Chin, V. T.
- Affiliations
- UNSW Sydney (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Wilson, Brooke E.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2019-12-21
- Volume
- 69
- Issue
- 3
- Pages
- 343-354
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11027824
- OpenAlex
- W2995658490
- Cited by
- 152
- References
- 57
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 21 · 2023: 26 · 2022: 21 · 2021: 23 · 2020: 24 · 2019: 1
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- antibiotics, immune checkpoint blockade, gut microbiota, overall survival, progression-free survival, solid tumors, lung cancer, renal cell carcinoma, urothelial carcinoma, melanoma, cancer immunotherapy outcomes
- MeSH terms
- Anti-Bacterial Agents, Humans, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.